New Analyses of Translarna™ (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

New Analyses of Translarna™ (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress


PTC Therapeutics, Inc. today announced the presentation of new analyses utilizing alternative methods to understand the progression of Duchenne muscular dystrophy and the benefits of Translarna in nonsense mutation Duchenne muscular dystrophy patients. A scientific presentation, “Slope analysis of 6-minute walk distance as an alternative method to determine treatment effect in trials in Duchenne muscular dystrophy” will be presented today during the Neuromuscular pathologies session. In addition, a poster entitled, “Use of a >= 5-second threshold in baseline time to stand from supine to predict disease progression in Duchenne muscular dystrophy” will be presented during the poster session on Friday. The 12th Annual European Pediatric Neurology Society Congress is being held at the Cite Internationale in Lyon, France.

https://www.duchennexchange.org/wp-content/uploads/2017/07/ptc.jpg